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Well Established: 
Insufficient milk supply is one of the most commonly reported reasons for 
discontinuation of infant breastfeeding. While evidence supports the efficacy of 
domperidone in initiating and maintaining milk supply, knowledge of how 
domperidone is actually used in clinical practice is scarce.  
Newly Expressed: 
The number of women dispensed domperidone increased significantly from <0.5% in 
2000 to >5% in 2010. Following a comparison to existing evidence, current practice 
appears to be largely based on anecdotal evidence, highlighting the need for well-
designed randomised controlled trials. 
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Abstract 
Background: Domperidone is often used to promote lactation among women who 
have difficulty breastfeeding.  
Objective: To examine prescribing and dispensing practices of domperidone at the 
Women’s and Children’s Hospital (WCH), Adelaide. 
Methods: A retrospective audit of domperidone dispensing among women with 
singleton pregnancies who delivered at the WCH between January 2000 and July 
2010 was undertaken. Women dispensed domperidone were identified using WCH 
Pharmacy Dispensing Records. Maternal and infant clinical data was obtained from 
the WCH Perinatal Statistics Collection. A case note audit for a random sample of 
261 of these women and their infants was undertaken to collect prescribing and 
additional clinical data. 
Results: From 2000 to 2010, 1,605 women were dispensed domperidone. There was 
a steady increase in the percentage of women dispensed domperidone, from <0.5% 
in 2000 to >5% of total WCH pregnancies in 2010. Over time, the percentage of 
women who received >1 domperidone dispensing remained consistent (20%), as did 
the median number of days (12) from delivery to first domperidone dispensing. 
Multiparous women were more likely to receive domperidone within 3 days 
following delivery compared to primiparous women (8% vs. 4%). Most women (80%) 
received directions to take domperidone according to a standard tapering dosing 
regimen over 12 days. Surprisingly, 60% of women had no documentation of being 
assessed by a lactation consultant.  
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Conclusion: From 2000 to 2010 there was a significant increase in domperidone 
dispensing. With a lack of clinical evidence to guide use, current practice appears to 
be based on anecdotal evidence.
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Background 
Exclusive breastfeeding for the first six months of life is recognised as the optimal 
form of nutrition to support the growth and development of term and preterm infants.1-3 
Breastfeeding has numerous short and long-term benefits. These include the psychological 
benefits of maternal–infant bonding,2, 4 and benefits to the infant including the provision of 
passive and long-lasting active immunity to infections,1, 3, 5 potential long-term improvements 
in intellectual development,2, 3 and reduced future risk of chronic medical conditions such as 
obesity and diabetes.6 
Despite the ability of the majority of mothers to be able to produce sufficient 
quantities of milk for their baby, given the correct support and information, insufficient milk 
supply, whether real or just perceived, is one of the most commonly reported reasons for 
discontinuation of infant breastfeeding.7 Mothers who are particularly vulnerable to 
difficulties breastfeeding, are those who deliver infants who are unwell and require 
supportive care following delivery, such as preterm infants.5, 8 In many cases these mothers 
are not able to breastfeed directly which, in addition to the stressful situation of having an 
unwell infant, can have a detrimental effect on milk supply. However, it is not only women of 
hospitalised infants who experience difficulty with lactation. Additional risk factors have been 
identified for difficulty initiating and/or maintaining milk supply including maternal illness, 
caesarean delivery, maternal smoking, previous breast surgery, mother-infant separation and 
indirect lactation (i.e. breast pump or manual milk expression).8 Furthermore, anxiety, 
fatigue and emotional stress in mothers can also contribute to poor lactation.9  
Perceived milk insufficiency can occur as a result of normal postpartum physical 
breast changes, such as the softening of the breasts around 10 to 14 days postpartum.8 This 
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perception can also be influenced by a lack of confidence in the mother, especially if they 
have not previously breastfed, lack of support from family and friends and having a limited 
understanding of lactation physiology.8 Additionally, infant symptoms such as irritability, 
crying and frequent feeding may all be misinterpreted as a lack of breast milk quality or 
quantity.8 In situations of perceived milk insufficiency, non-pharmacological strategies, such 
as education in correct infant positioning and attachment at the breast, increasing frequency 
of breastfeeds and mechanical expression are usually sufficient to increase a woman's milk 
supply.1, 8, 10, 11 
However, in some situations the use of non-pharmacological strategies are 
insufficient and some women still struggle to produce or maintain adequate milk supply. This 
necessitates the need for pharmacological intervention with medications used to augment 
lactation, known as galactagogues. The most widely studied and commonly used 
galactagogues include dopamine receptor antagonists, metoclopramide and domperidone, 
which have both been demonstrated to be effective treatments for initiation and 
maintenance of lactation.2, 5, 9, 10, 12-14 
Both of these medications elicit their actions by blocking dopamine D2 receptors in 
the anterior pituitary to stimulate prolactin release. A key difference between agents is that 
domperidone exerts its pharmacological effects in the peripheral nervous system (PNS), 
while metoclopramide acts centrally.15 While metoclopramide has been used extensively in 
the past, domperidone is preferred as it does not cross the blood-brain barrier, is associated 
with less central nervous system (CNS) side effects (i.e. fatigue, irritability, depression), and is 
secreted in only small amounts into breast milk, compared with metoclopramide.8, 9, 11   
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In recent years it has become more common to recommend that mothers with 
insufficient milk supply (whether real or just perceived) be prescribed dompridone to 
increase milk production and supply. In recognition of this, the Drug and Therapeutics 
Committee at the Women’s and Children’s Hospital (WCH) approved the use of a 
standardised ‘Domperidone Prescription Sheet for Increasing Milk Supply’. This guideline was 
aimed at standardising domperidone prescribing to a fixed dose-tapering schedule over 12 
days. This schedule consisted of one tablet three times a day for five days, followed by one 
tablet twice a day for three days and then one tablet once a day for four days. Despite its 
approval and use since 2005, there are concerns that the standardised prescription regimen is 
largely based on anecdotal evidence rather than evidence from randomized controlled trials. 
Furthermore, there are concerns that the introduction of this regimen has led to an increase 
in the prescribing of domperidone prior to adequate investigation of the effects on non-
pharmacological interventions to increase milk supply and variability in the time to treatment 
initiation. Hence, the use of domperidone in clinical practice is of interest. Therefore, the aim 
of this study was to undertake a retrospective audit of the use of domperidone as a 
galactagogue at a major tertiary teaching hospital over a 10-year period.  
 
Method 
This was a retrospective audit of women dispensed domperidone who delivered at 
the WCH in South Australia, Australia, between January 2000 and July 2010. The WCH is a 
specialist metropolitan tertiary level teaching hospital and South Australia’s largest maternity 
and obstetric service provider, caring for over 4,000 pregnancies each year. The study utilised 
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linkable health administrative data within the WCH, which included the WCH Perinatal 
Statistics Collection and the WCH Hospital Pharmacy Dispensing Records. 
Data relating to women dispensed domperidone were obtained from the WCH 
Pharmacy Dispensing Records, which contains data on all medications dispensed at the 
hospital from January 2000. Data available from the dispensing records include dispensing 
date, type of dispensing (i.e. inpatient, outpatient), quantity supplied and dispensing 
directions. The electronic dispensing records were then matched to all births recorded in the 
WCH Perinatal Statistics Collection, using each individual’s unique hospital identifier number.  
Women were included in the audit if they delivered a singleton infant and received a 
dispensing for domperidone within 6 months of the date of delivery. This enabled an overall 
assessment and evaluation of the prescribing and dispensing trends for domperidone over 
the 10-year period. In addition to the overall assessment, a case note audit was undertaken 
to obtain prescribing directions and more in-depth clinical data, available only in paper-based 
medical records, for a random sample of mothers and their corresponding infants. To obtain 
the random sample, women dispensed domperidone were first stratified according to year of 
delivery. Where the number of women dispensed domperidone in a particular year was less 
than 30, all women for that year were included in the case note audit. Where the number of 
women dispensed domperidone was greater than 30, a computer-generated random sample 
was selected. This resulted in a random selection of 261 corresponding mother and infant 
case notes. Data collected from case notes included dose and duration of domperidone 
treatment, whether mothers saw a lactation consultant and/or were admitted to the 
breastfeeding unit and whether they directly requested domperidone.  
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Information on maternal age, race, smoking status and parity and infant birth weight, 
gestational age and admission to hospital was obtained from the Perinatal Statistics 
Collection. Clinical Information Services (CIS) at the WCH is responsible for maintaining the 
Perinatal Statistics Collection. Data is collected regarding the pregnancy and outcome of 
every live birth and late fetal death occurring at the WCH, including data on every infant 
admitted to the neonatal intensive care unit (NICU) and special care baby unit (SCBU). The 
data are collected according to the guidelines of the Pregnancy Outcome Unit of the South 
Australian Department of Health for the Supplementary Birth Records (SBRs) and in 
consultation with the senior clinicians at the WCH. The information in the Perinatal Statistics 
Collection has been previously validated and is reliable when compared with hospital case 
records.16 
The estimated length of gestational age at delivery is recorded in the Perinatal 
Statistics Collection and is based on the last menstrual period and ultrasound examination. 
Parity was defined as no previous deliveries (nulliparity) or 1 or more previous deliveries. 
Maternal race or ethnic group was classified as Caucasian, Asian or other. Data on smoking 
are routinely collected during the first antenatal visit and therefore reflects smoking status 
during early pregnancy. The smoking variable was categorised into non-smokers and 
smokers. According to documentation in the case notes, women were classified as being 
admitted to the breastfeeding unit (BFU) and/or being assessed by a lactation consultant.  
All data analysis was undertaken on de-identified data. Descriptive statistics were 
used to report frequencies, means, medians and percentage. Univariate categorical analyses 
using the chi-square test or Fisher’s exact test, where appropriate, were conducted. The 
length of time between childbirth and the first domperidone dispensing was identified and 
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presented as median number of days between childbirth to first domperidone dispensing. A 
quartile regression was performed to assess the length of time from birth to first 
domperidone dispensing from January 2000 to July 2010.  
The number of repeat domperidone dispensings was calculated to investigate any 
change in domperidone dispensing over the 10-year period. When calculating the numbers 
of domperidone treatment courses a mother received, a standard rule of ‘6 days between 
dispensing dates’ was used to identify the next course of domperidone treatment. 
Agreement between the directions recorded on the original prescriptions filed in the 
case notes were compared to directions recorded in the dispensing data before and after the 
introduction of the standardised domperidone prescription chart.  
Statistical analyses were performed using SPSS 19 (Statistical Package for the Social 
Sciences) and STATA 11 (Stata, College Station, TX). Statistical significance was defined as a 2-
sided P value of 0.05. This project was approved by the Human Research Ethics Committees 
of The University of South Australia and the Women’s and Children’s Health Network in 




A total of 1,605 (3.6%) women who delivered at the WCH between January 2000 and 
July 2010 were dispensed domperidone. Characteristics of women who were dispensed 
domperidone are shown in Table 1. The mean age of women dispensed domperidone was 
30.5 years (± 6.2). The majority of women were Caucasian (79%), primiparous (60%), non-
smokers (78%) and had normal vaginal delivery (56%).  
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The number of women dispensed domperidone increased steadily over the 10-year 
period from less than 1% in 2000 to approximately 5% in 2010 (Figure 1). Over the 10-year 
period there was no significant difference in the number of days between childbirth and first 
domperidone dispensing, with the majority of women (94%) dispensed domperidone at least 
4 or more days following childbirth. A further sub-analysis demonstrated, however, that 
multiparous women were more likely to be dispensed domperidone within 3 days following 
childbirth compared to primiparous women (8% vs. 4%; P<0.01). The majority of women 
included in the audit were dispensed a single course of domperidone (81%), with the 
proportion of women receiving multiple courses of domperidone remaining consistent over 
time. Mothers of preterm infants were more likely to receive a repeat domperidone 
dispensing than mothers of term infants (35% vs. 10%; P<0.01) 
Case Note Audit 
Out of the 261 pairs of mother and infant case notes randomly selected, 215 pairs of 
case notes (82.4%) were reviewed. Forty-six pairs of case notes were unavailable from 
medical records. When maternal, or infant, or both case notes were unavailable, the pair of 
case notes was excluded. 
For approximately one third (31%) of women dispensed domperidone it was 
documented that they were admitted to the breastfeeding unit, with a further 9% 
documented as being assessed by a lactation consultant. Mothers of preterm infants were 
more likely to be admitted to the breastfeeding unit and/or be assessed by a lactation 
consultant than mothers of term infants (63% vs. 19%; P<0.01). In addition, primiparous 
women were more likely to be admitted to the breastfeeding unit and/or be assessed by a 
lactation consultant than multiparous women (50% vs. 25.8%; P<0.01). 
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It was documented that a small percentage (5%) of women directly requested a 
prescription for domperidone with a sub-analysis demonstrating that multiparous women 
were more likely to directly request domperidone than primiparous women (9.0% vs. 2.4%; 
P=0.03).  
Furthermore, prior to the introduction of the standardised domperidone dose-
tapering schedule in 2005, there was 93% agreement between the directions on the original 
prescription and those on the dispensed medication. After 2005, there was 75% agreement 
between the directions on the original prescription and those on the dispensed medication. 
This decrease in the level of agreement was statistically significant (P=0.03). The most 
commonly dispensed direction over thde 10 year period was the standardised domperidone 
dose-tapering schedule (96.4%).  
Discussion 
From January 2000 to July 2010 there was a steady increase in the number of women 
dispensed domperidone at the WCH, from less than 1% of all pregnancies in 2000 to 
approximately 5% in 2010. The infrequent use of domperidone between 2000 and 2002 may 
have been due to the preferred use of metoclopramide as the first line treatment for 
managing insufficient breast milk supply during that time. The publication of a randomised 
controlled trial highlighting the effectiveness of domperidone in increasing milk supply in 
2001,2 could explain the steady increase in domperidone use from 2002 onwards. In 
response to the apparent increase in demand, a patient information sheet titled ‘Medications 
for increasing breast milk supply’ was introduced at WCH in March 2003. The introduction of 
this patient information sheet may have led to increased dispensing due to increased patient 
and prescriber awareness of the use of domperidone for this indication.  
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Only half of the infants identified in the current study were preterm and/or admitted 
to the NICU or SCBU. This is despite the fact that the majority of previous studies evaluating 
the use of domperidone as a galactagogue comprised of mothers of infants who were 
preterm and/or admitted to NICU’s,2, 5, 12) 
The standardised domperidone dose-tapering schedule, introduced in 2005, was the 
most commonly used direction at the WCH, with the majority of women prescribed 
domperidone for a total of 12 days. Previously published literature provides inconsistent 
evidence regarding the most appropriate dose, duration, population and time to initiate 
domperidone treatment, making it difficult to generate clear evidence-based guidelines for 
the use of domperidone as a galactagogue. However, anecdotal evidence and clinical 
experiences recommended taking domperidone for at least six weeks in order to observe its 
effectiveness.17 
Given evidence that not all women respond to domperidone and that that the use of 
domperidone should be discontinued if it does not produce the desired response,18 it could 
be questioned whether a 12 day course is sufficient for evaluating whether domperidone 
would be effective in increasing milk production and supply. The fact that more than 30% of 
mothers who delivered preterm infants received more than one treatment course of 
domperidone adds further evidence to suggest a longer initial treatment course could be 
required to ensure maximal effectiveness. 
Anecdotally, a reduction in the average length of a postnatal hospital stay at the WCH 
could be expected to result in an increasing number of women dispensed domperidone 
earlier following delivery. However, the number of days between delivery and first 
domperidone dispensing did not change over the 10-year period. Given 2 to 3 days is 
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required for lactation to become well established,19 the use of domperidone within the first 3 
days following delivery could be considered inappropriate. It is positive that few women 
(5.5%) received a domperidone dispensing within the first 3 days following delivery. 
However, as it was documented that only a third of these women were admitted to the 
breastfeeding unit and/or saw a lactation consultant, it raises concerns as to whether women 
are being dispensed domperidone prior to the trial of appropriate non-pharmacological 
interventions to increase milk production and supply.  
It is interesting to note that multiparous women were more likely to receive a 
domperidone dispensing within 3 days following delivery compared to primiparous women. 
It could be speculated that multiparous women, with lactation difficulties in a previous 
pregnancy, may have received domperidone treatment earlier as they may expect to re-
experience similar breastfeeding difficulties and therefore request domperidone earlier. 
Conversely, primiparous women will have to first attempt breastfeeding themselves prior to 
realising they have difficulties breastfeeding20 and may also be naive to the existence of 
domperidone and its use as a galactagogue. This is also in accordance with the current 
finding that multiparous women were more likely to directly request domperidone than 
primiprous women. 
Following the introduction of the standardised dose-tapering schedule, there 
appeared to be an increased level of disagreement between original prescription directions 
and those recorded in the dispensing database. In the majority of cases (primarily post 2005), 
the original directions were changed to reflect those of the standard dose-tapering schedule 
commonly used at the WCH. The standard dosing schedule may not always be appropriate, 
as it does not enable the prescriber to individually tailor treatment (i.e. the individual may 
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require a higher dose, or longer duration of treatment). Importantly, it appears that no 
information was documented in the maternal or infant case note regarding the change in 
dispensing directions, or if the original prescriber was consulted regarding the change. It is 
possible that the original prescriber was contacted and that changes were only made on the 
copy sent to the pharmacy department and not documented in the patient’s case notes. 
Therefore, it is of concern that women may become confused if the original directions on the 
prescription are subsequently changed when dispensed by the pharmacist.  
It is clear that domperidone should not be used as a substitute for, or as an 
alternative to, effective non-pharmacological breastfeeding support and encouragement. It is 
imperative for women who have breastfeeding difficulties to be assessed by a lactation 
consultant and/or be admitted to BFU to ensure modifiable risk factors of poor breastfeeding 
are addressed prior to the prescription of any galactagogue. It is of concern that only 40% of 
mother’s dispensed domperidone were admitted to the BFU and/or received specialist 
advice from a lactation consultant. However, it is possible that the number of women who 
received advice from a lactation consultant was underestimated, due to poor documentation 
in case notes and/or the possibility that some women were assessed by a lactation 
consultant outside of the WCH.  
There are several limitations in the current study. Firstly, this study did not include a 
control group of women who did not receive a dispensing for domperidone. It was therefore 
not possible to assess and identify risk factors for lactation failure. Secondly is the reliance on 
WCH pharmacy dispensing data to determine domperidone use. The total use of 
domperidone among the cohort of women in the current study is likely to be 
underestimated, as some women may have been prescribed and dispensed domperidone 
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outside of the WCH. Without prospectively following a cohort of women after delivery, there 
is no way to identify how domperidone is being prescribed in the community setting. 
Dispensing directions were not always available. For example, inpatient supplies of 
domperidone are not dispensed with directions. In addition, dispensing directions were not 
available after September 2009 due to a change in the dispensing database program. Thirdly, 
not all case notes identified in the original random sampling procedure were available to 
examine, and the quality of data collected was dependant on the quality of documentation in 
case notes. Lastly, not all of the original prescriptions could be found in the case notes.  
This audit of domperidone use as a galactagogue highlights a number of key areas for 
future research. There is clear need to ensure all women have access to appropriate non-
pharmacological support and advice regarding breastfeeding. Furthermore, there is a need to 
identify the most effective time to initiate domperidone treatment after delivery, recognising 
that this may be different for primiparous and multiparous women. In addition, further 
evaluation is required on the most appropriate dose and duration of treatment and whether 
dose tapering is required and how this should be undertaken. It would also be useful to 
investigate why some women do and do not respond to treatment with domperidone, which 
may allow further medication tailoring.  
Conclusion 
In conclusion, the retrospective audit at WCH indicates an overall increase in the 
percentage of mothers being dispensed domperidone in the last 10 years. With a lack of 
clinical evidence to guide use, current practice appears to be based on anecdotal evidence, 
highlighting the need for well-designed randomised controlled trials to support evidence-
based practice on the use of domperidone as a galactagogue. 
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Table 1. Characteristics of Mothers who received a domperidone dispensing 
Mean maternal age (± SD), years 30.5 ± 6.2 






















Method of delivery, n (%) 





Number of days between delivery and domperidone 
dispensing, n (%) 
 
     0-3 89 (6) 
     4 1,516 (95) 
Single Course of Domperidone dispensed, n (%) 1,300 (81) 
Mother admitted to breastfeeding unit, n (%)† 67 (31) 
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Mother assessed by lactation consultant, but not 
admitted to breastfeeding unit, n (%)† 
19 (9) 
Domperidone directly requested by mother, n (%)† 11 (5) 
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Table 2. Characteristics of Infants of Mothers who received a dispensing for domperidone 
Gestational age, n (%): 
     < 37 weeks 




Birth weight, n (%): 
     < 2500 g 




Admitted to Neonatal Ward (e.g. NICU), n (%): 
     Yes  
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Figure 1. Percentage of women dispensed domperidone according to total number of 
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